PMID- 31819525
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220411
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 12
DP  - 2019
TI  - miR-424-5p Promotes Proliferation, Migration and Invasion of Laryngeal Squamous 
      Cell Carcinoma.
PG  - 10441-10453
LID - 10.2147/OTT.S224325 [doi]
AB  - BACKGROUND: Recent studies revealed that miR-424-5p regulates the malignant 
      behavior of multiple cancer types. However, the expression and function of 
      miR-424-5p in laryngeal squamous cell carcinoma (LSCC) is unclear. PURPOSE: This 
      study aimed to evaluate the association of miR-424-5p level with clinical 
      features of LSCC and investigate the effect and potential mechanism of miR-424-5p 
      on LSCC progression. METHODS: The expression of miR-424-5p in LSCC and paired 
      adjacent normal margin (ANM) tissues from 106 patients with LSCC were analyzed by 
      quantitative PCR (qPCR), and clinical significance was analyzed. Target genes of 
      miR-424-5p were predicted, followed by functional annotation. The functional role 
      of miR-424-5p in LSCC was investigated by molecular and cellular experiments with 
      LSCC cell lines, with flow cytometry used for cell cycle analysis. In addition, 
      miR-424-5p regulation of the predicted target gene cell adhesion molecule 1 
      (CADM1) was validated by qPCR, Western blot analysis and luciferase reporter 
      assay. RESULTS: miR-424-5p was upregulated in LSCC versus ANM tissues. High 
      miR-424-5p level was significantly associated with poor differentiation, advanced 
      tumor stage and cervical lymph node metastasis. Bioinformatics analysis showed 
      that miR-424-5p target genes are mainly enriched in biological processes of the 
      cell cycle, cell division, and negative regulation of cell migration, and were 
      involved in multiple cancer-related pathways. Overexpression of miR-424-5p 
      promoted proliferation, migration, invasion, and adhesion of LSCC cells and 
      affected the cell cycle progression. Additionally, CADM1 was a direct target of 
      miR-424-5p in LSCC cells. CONCLUSION: miR-424-5p functions as an oncogene to 
      promote the aggressive progression of LSCC, and CADM1 is a direct downstream 
      target of miR-424-5p in LSCC cells. miR-424-5p may be a potential therapeutic 
      target in LSCC.
CI  - (c) 2019 Li et al.
FAU - Li, Yujun
AU  - Li Y
AUID- ORCID: 0000-0002-9413-6018
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical 
      University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Department of Otolaryngology Head & Neck Surgery, The First Hospital of Shanxi 
      Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Otolaryngology Head & Neck Surgery Research Institute, Shanxi Medical University, 
      Taiyuan, Shanxi 030001, People's Republic of China.
AD  - The Key Scientific and Technological Innovation Platform for Precision Diagnosis 
      and Treatment of Head and Neck Cancer, Shanxi Province, Taiyuan 030001, Shanxi, 
      People's Republic of China.
FAU - Liu, Jie
AU  - Liu J
AD  - Department of Head and Neck Surgical Oncology, National Cancer Center, National 
      Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, Beijing 100021, People's Republic of 
      China.
FAU - Hu, Wanglai
AU  - Hu W
AD  - School of Basic Medical Science, Anhui Medical University, Hefei, Anhui 230027, 
      People's Republic of China.
FAU - Zhang, Yuliang
AU  - Zhang Y
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical 
      University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Department of Otolaryngology Head & Neck Surgery, The First Hospital of Shanxi 
      Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Otolaryngology Head & Neck Surgery Research Institute, Shanxi Medical University, 
      Taiyuan, Shanxi 030001, People's Republic of China.
AD  - The Key Scientific and Technological Innovation Platform for Precision Diagnosis 
      and Treatment of Head and Neck Cancer, Shanxi Province, Taiyuan 030001, Shanxi, 
      People's Republic of China.
FAU - Sang, Jiangwei
AU  - Sang J
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical 
      University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Department of Otolaryngology Head & Neck Surgery, The First Hospital of Shanxi 
      Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Otolaryngology Head & Neck Surgery Research Institute, Shanxi Medical University, 
      Taiyuan, Shanxi 030001, People's Republic of China.
AD  - The Key Scientific and Technological Innovation Platform for Precision Diagnosis 
      and Treatment of Head and Neck Cancer, Shanxi Province, Taiyuan 030001, Shanxi, 
      People's Republic of China.
FAU - Li, Huizheng
AU  - Li H
AUID- ORCID: 0000-0003-3954-6118
AD  - Department of Otolaryngology Head & Neck Surgery, Dalian Municipal Friendship 
      Hospital, Dalian, Liaoning 116001, People's Republic of China.
FAU - Ma, Teng
AU  - Ma T
AD  - Department of Cellular and Molecular Biology, Beijing Chest Hospital, Beijing 
      Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, 
      Beijing 101149, People's Republic of China.
FAU - Bo, Yunfeng
AU  - Bo Y
AD  - Department of Pathology, Shanxi Cancer Hospital, Shanxi Medical University, 
      Taiyuan, Shanxi 030000, People's Republic of China.
FAU - Bai, Tao
AU  - Bai T
AD  - Department of Pathology, The First Hospital of Shanxi Medical University, 
      Taiyuan, Shanxi 030001, People's Republic of China.
FAU - Guo, Huina
AU  - Guo H
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical 
      University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Department of Otolaryngology Head & Neck Surgery, The First Hospital of Shanxi 
      Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Otolaryngology Head & Neck Surgery Research Institute, Shanxi Medical University, 
      Taiyuan, Shanxi 030001, People's Republic of China.
AD  - The Key Scientific and Technological Innovation Platform for Precision Diagnosis 
      and Treatment of Head and Neck Cancer, Shanxi Province, Taiyuan 030001, Shanxi, 
      People's Republic of China.
FAU - Lu, Yan
AU  - Lu Y
AD  - Department of Otolaryngology Head & Neck Surgery, The First Hospital, Jinzhou 
      Medical University, Jinzhou 121001, Liaoning, People's Republic of China.
FAU - Xue, Xuting
AU  - Xue X
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical 
      University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Department of Otolaryngology Head & Neck Surgery, The First Hospital of Shanxi 
      Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Otolaryngology Head & Neck Surgery Research Institute, Shanxi Medical University, 
      Taiyuan, Shanxi 030001, People's Republic of China.
AD  - The Key Scientific and Technological Innovation Platform for Precision Diagnosis 
      and Treatment of Head and Neck Cancer, Shanxi Province, Taiyuan 030001, Shanxi, 
      People's Republic of China.
FAU - Niu, Min
AU  - Niu M
AUID- ORCID: 0000-0003-2445-7075
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical 
      University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Department of Otolaryngology Head & Neck Surgery, The First Hospital of Shanxi 
      Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Otolaryngology Head & Neck Surgery Research Institute, Shanxi Medical University, 
      Taiyuan, Shanxi 030001, People's Republic of China.
AD  - The Key Scientific and Technological Innovation Platform for Precision Diagnosis 
      and Treatment of Head and Neck Cancer, Shanxi Province, Taiyuan 030001, Shanxi, 
      People's Republic of China.
FAU - Ge, Shanshan
AU  - Ge S
AD  - Health Management Center, the First Hospital of Shanxi Medical University, 
      Taiyuan 030001, Shanxi, People's Republic of China.
FAU - Wen, Shuxin
AU  - Wen S
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical 
      University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Department of Otolaryngology Head & Neck Surgery, The First Hospital of Shanxi 
      Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Otolaryngology Head & Neck Surgery Research Institute, Shanxi Medical University, 
      Taiyuan, Shanxi 030001, People's Republic of China.
AD  - The Key Scientific and Technological Innovation Platform for Precision Diagnosis 
      and Treatment of Head and Neck Cancer, Shanxi Province, Taiyuan 030001, Shanxi, 
      People's Republic of China.
FAU - Wang, Binquan
AU  - Wang B
AUID- ORCID: 0000-0002-3686-0219
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical 
      University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Department of Otolaryngology Head & Neck Surgery, The First Hospital of Shanxi 
      Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Otolaryngology Head & Neck Surgery Research Institute, Shanxi Medical University, 
      Taiyuan, Shanxi 030001, People's Republic of China.
AD  - The Key Scientific and Technological Innovation Platform for Precision Diagnosis 
      and Treatment of Head and Neck Cancer, Shanxi Province, Taiyuan 030001, Shanxi, 
      People's Republic of China.
FAU - Gao, Wei
AU  - Gao W
AUID- ORCID: 0000-0001-7836-2851
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical 
      University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Department of Otolaryngology Head & Neck Surgery, The First Hospital of Shanxi 
      Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Otolaryngology Head & Neck Surgery Research Institute, Shanxi Medical University, 
      Taiyuan, Shanxi 030001, People's Republic of China.
AD  - The Key Scientific and Technological Innovation Platform for Precision Diagnosis 
      and Treatment of Head and Neck Cancer, Shanxi Province, Taiyuan 030001, Shanxi, 
      People's Republic of China.
FAU - Wu, Yongyan
AU  - Wu Y
AUID- ORCID: 0000-0003-1669-3860
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical 
      University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Department of Otolaryngology Head & Neck Surgery, The First Hospital of Shanxi 
      Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
AD  - Otolaryngology Head & Neck Surgery Research Institute, Shanxi Medical University, 
      Taiyuan, Shanxi 030001, People's Republic of China.
AD  - The Key Scientific and Technological Innovation Platform for Precision Diagnosis 
      and Treatment of Head and Neck Cancer, Shanxi Province, Taiyuan 030001, Shanxi, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20191129
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6890199
OTO - NOTNLM
OT  - laryngeal squamous cell carcinoma
OT  - miR-424-5p
OT  - migration and invasion
OT  - oncogenic miRNA
OT  - proliferation
COIS- The authors report no conflict of interest in this work.
EDAT- 2019/12/11 06:00
MHDA- 2019/12/11 06:01
PMCR- 2019/11/29
CRDT- 2019/12/11 06:00
PHST- 2019/07/23 00:00 [received]
PHST- 2019/11/18 00:00 [accepted]
PHST- 2019/12/11 06:00 [entrez]
PHST- 2019/12/11 06:00 [pubmed]
PHST- 2019/12/11 06:01 [medline]
PHST- 2019/11/29 00:00 [pmc-release]
AID - 224325 [pii]
AID - 10.2147/OTT.S224325 [doi]
PST - epublish
SO  - Onco Targets Ther. 2019 Nov 29;12:10441-10453. doi: 10.2147/OTT.S224325. 
      eCollection 2019.